Saint Luke's Newsroom

TCTMD: PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF
Dapagliflozin eases symptoms and physical limitations among patients who have heart failure with preserved ejection fraction (HFpEF) within a relatively short time period.
Cardiovascular Business: Dapagliflozin significantly improves HFpEF symptoms
Treatment with dapagliflozin improves the symptoms of patients with heart failure with preserved ejection fraction (HFpEF), according to new findings presented at the Heart Failure Society of America's Annual Scientific Meeting.
Health News You Can Use: Importance of Early Detection for Breast Cancer
This week we are talking with Dr. Elizabeth Cathcart-Rake, medical breast oncologist at Saint Luke’s Cancer Institute about preventive screenings, why early detection is key, and risk factors that women should keep in mind for breast cancer.  
MD edge: PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF
The SGLT2 inhibitor dapagliflozin scored a clear win in a randomized, controlled trial with more than 300 U.S. patients with heart failure with preserved ejection fraction (HFpEF).
Medpage Today: SGLT2 Inhibitor Eases Symptoms for HFpEF Patients
Symptoms of heart failure with preserved ejection fraction (HFpEF) improved with dapagliflozin (Farxiga) therapy, the PRESERVED-HF trial showed.
Saint Luke's Mid America Heart Institute
PRESERVED-HF trial demonstrates substantial improvements in symptoms, physical limitations and exercise function with dapagliflozin in individuals with heart failure with preserved ejection fraction (HFpEF)
6.2 million people in the United States are living with heart failure, and the majority are diagnosed with heart failure with preserved ejection fraction (HFpEF).
KMBC: Saint Luke's Mid America Heart Institute performs its 900th heart transplant
KMBC talked to Dr. Andrew Kao about the significance of the big milestone and lucky number 900 to learn his touching story.
FOX4: Kansas City doctors excited to cheer for Laurent Duvernay-Tardif’s return to Chiefs
Dr. Andrew Schlachter, pulmonologist and critical care physician at Saint Luke's, talks to FOX4 about Duvernay-Tardif returning to play with the Chiefs this season. 
Health News You Can Use: Upcoming Flu Season and COVID-19 Booster Shots
We’re talking about COVID-19 boosters and flu shots, the upcoming influenza season, and how the community can help health care workers in the months ahead.